Krystal Biotech, Inc. (NASDAQ:KRYS) Forecasted to Post Q2 2024 Earnings of $0.37 Per Share

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - HC Wainwright increased their Q2 2024 earnings per share (EPS) estimates for Krystal Biotech in a report released on Monday, May 6th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of $0.37 per share for the quarter, up from their previous forecast of $0.10. HC Wainwright currently has a "Buy" rating and a $200.00 price target on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $1.82 per share. HC Wainwright also issued estimates for Krystal Biotech's Q3 2024 earnings at $0.31 EPS, Q4 2024 earnings at $0.18 EPS and FY2024 earnings at $0.89 EPS.

Several other research analysts also recently weighed in on KRYS. Stifel Nicolaus restated a "buy" rating and set a $204.00 target price (up from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. Guggenheim upped their price objective on shares of Krystal Biotech from $130.00 to $175.00 and gave the company a "buy" rating in a report on Tuesday, February 27th. William Blair reiterated an "outperform" rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. Finally, Citigroup raised their price target on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a "buy" rating in a report on Tuesday, February 27th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Krystal Biotech currently has an average rating of "Buy" and an average price target of $171.00.

Krystal Biotech Price Performance

NASDAQ KRYS traded down $4.08 on Wednesday, hitting $157.68. The stock had a trading volume of 244,959 shares, compared to its average volume of 363,836. The business's fifty day moving average price is $168.76 and its 200 day moving average price is $134.27. The stock has a market cap of $4.50 billion, a price-to-earnings ratio of 1,971.25 and a beta of 0.91. Krystal Biotech has a 52-week low of $86.03 and a 52-week high of $189.97.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, May 6th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.20 by ($0.17). The firm had revenue of $45.25 million for the quarter, compared to analyst estimates of $47.37 million. During the same quarter in the prior year, the company earned ($1.76) EPS. The business's quarterly revenue was up 452400.0% on a year-over-year basis.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. increased its position in shares of Krystal Biotech by 111.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company's stock valued at $83,000 after buying an additional 379 shares in the last quarter. Quest Partners LLC acquired a new stake in Krystal Biotech in the 4th quarter valued at $127,000. Pier 88 Investment Partners LLC purchased a new stake in Krystal Biotech in the 4th quarter worth $145,000. Headlands Technologies LLC acquired a new position in Krystal Biotech during the first quarter worth $291,000. Finally, Fox Run Management L.L.C. purchased a new position in Krystal Biotech during the third quarter valued at $219,000. Hedge funds and other institutional investors own 86.29% of the company's stock.

Insiders Place Their Bets

In related news, CAO Kathryn Romano sold 5,000 shares of the firm's stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total transaction of $829,400.00. Following the sale, the chief accounting officer now directly owns 12,936 shares of the company's stock, valued at $2,145,823.68. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the transaction, the insider now owns 1,550,882 shares of the company's stock, valued at $265,138,786.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Kathryn Romano sold 5,000 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total transaction of $829,400.00. Following the sale, the chief accounting officer now directly owns 12,936 shares in the company, valued at $2,145,823.68. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,087 shares of company stock valued at $6,210,591. Company insiders own 14.10% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).